Kiromic Biopharma, Inc. is a clinical stage biotherapeutics company, which engages in DIAMOND AI and discovers, validates, and develops cell and gene therapies with a therapeutic focus on immuno-oncology. The firm is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.